CSL Behring’s affiliate company in Switzerland and Enable Injections have agreed to a long-term development plan for a new and innovative drug delivery system.

To be developed, manufactured and sold by Enable to CSL Behring, the new device seeks to improve the comfort, convenience and treatment compliance for patients suffering from rare and serious diseases.

Enable’s new treatment administration device is specifically designed for subcutaneous dosing and will be used by CSL Behring along with one of its products on an exclusive worldwide basis.

CSL Behring Global Commercial Operations executive vice-president Bob Repella said: "Through our collaboration with Enable Injections, we hope to bring patients a delivery option that makes administration of their therapy easier, helps improve treatment compliance and offers them greater freedom and flexibility to treat their condition in a way that fits their individual needs."

Under the agreement, CSL Behring can opt to subsequently add more products and extend the agreement term for additional periods.

Enable will receive an upfront payment and specific milestone payments over the next several years as well as additional royalty payments.

The companies did not disclose further terms of the agreement; however, both the parties have agreed to discuss other potential subcutaneous product collaborations.